{"id":"W3086667064","doi":"10.25251/skin.4.supp.67","title":"Duration of Response and Progression-Free Survival with Sonidegib 200 Mg Once Daily Until Disease Progression or Start of New Antineoplastic Therapy in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month, Randomized, Double-Blind","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"SKiN Health","funders":"","keywords":"Oncology; Internal medicine; Medicine; Progression-free survival; Disease; Duration (music); Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001393444,0.0003147164,0.001330517,0.0001502939,0.00007382188,0.000005657887,0.0003455422,0.00006373404,0.00001332973],"category_scores_gemma":[0.001794592,0.0001215468,0.00008694021,0.0005761238,0.0009266696,0.0001078215,0.00009755779,0.0004028935,1.046382e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005848431,"about_ca_system_score_gemma":0.001133041,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006434984,"about_ca_topic_score_gemma":0.0001232031,"domain_scores_codex":[0.9958825,0.0005661762,0.001415504,0.0002458236,0.001636093,0.0002539216],"domain_scores_gemma":[0.9945771,0.001689087,0.002241863,0.0004711897,0.0007679953,0.0002527734],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8959624,0.00034741,0.09469686,0.0003036794,0.0001546707,0.0002657425,0.004773819,0.0003664641,0.001010937,0.000001239984,0.0003616001,0.001755213],"study_design_scores_gemma":[0.7537016,0.02476916,0.2028006,0.007338013,0.0008733592,0.0002329126,0.001637583,0.0002612862,0.008067212,0.00002996019,0.00007629934,0.0002120218],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872905,0.002961672,0.0001465865,0.007195462,0.0001579663,0.002159109,0.00002188953,0.000004857934,0.00006194606],"genre_scores_gemma":[0.9982992,0.0005342282,0.0007589693,0.00009668826,0.0001855537,0.000008299908,0.000004177301,0.00003693364,0.00007595271],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1422608,"threshold_uncertainty_score":0.4956535,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01571963843424404,"score_gpt":0.2695627125944479,"score_spread":0.2538430741602039,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}